AbCellera Biologics Inc. Increase (Decrease) in Other Operating Assets
AbCellera Biologics Inc. (ABCL) reported Increase (Decrease) in Other Operating Assets of -$1.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-05
- AbCellera Biologics Inc. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was -$3.58M.
- AbCellera Biologics Inc. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was $1.74M.
- AbCellera Biologics Inc. increase (decrease) in other operating assets for the quarter ending 2025-12-31 was -$3.07M.
- AbCellera Biologics Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was -$628.00K.
- AbCellera Biologics Inc. increase (decrease) in other operating assets for fiscal 2025 was -$17.15M.
- AbCellera Biologics Inc. increase (decrease) in other operating assets for fiscal 2024 was -$5.95M.
- AbCellera Biologics Inc. increase (decrease) in other operating assets for fiscal 2023 was -$18.25M, a 1427.49% decline from fiscal 2022.
- AbCellera Biologics Inc. increase (decrease) in other operating assets for fiscal 2022 was $1.38M, a 59.33% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 6 month as first filed | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 9 month as first filed | Increase (Decrease) in Other Operating Assets 12 month | Increase (Decrease) in Other Operating Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.84M 10-Q · filed 2026-08-05 | -$4.91M derived: sum of 3 quarters · filed 2026-08-05 | -$5.54M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $1.74M 10-Q · filed 2026-05-11 | -$1.33M derived: sum of 2 quarters · filed 2026-05-11 | -$1.96M derived: sum of 3 quarters · filed 2026-05-11 | -$8.09M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | -$3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$3.70M derived: sum of 2 quarters · filed 2026-02-24 | -$9.83M derived: sum of 3 quarters · filed 2026-08-05 | -$17.15M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | -$628.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$6.76M derived: sum of 2 quarters · filed 2026-08-05 | -$14.08M 10-Q · filed 2025-11-06 | -$19.02M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | -$6.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$13.45M 10-Q · filed 2026-08-05 | -$18.40M derived: sum of 3 quarters · filed 2026-08-05 | -$20.88M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | -$7.32M 10-Q · filed 2026-05-11 | -$12.27M derived: sum of 2 quarters · filed 2026-05-11 | -$14.75M derived: sum of 3 quarters · filed 2026-05-11 | -$16.88M derived: sum of 4 quarters · filed 2026-05-11 | |||
| 2024-12-31 | -$4.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$7.43M derived: sum of 2 quarters · filed 2026-02-24 | -$9.56M derived: sum of 3 quarters · filed 2026-02-24 | -$5.95M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | -$2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.61M derived: sum of 2 quarters · filed 2025-11-06 | -$1.01M 10-Q · filed 2025-11-06 | -$14.94M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-06-30 | -$2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.47M 10-Q · filed 2025-08-07 | -$12.46M derived: sum of 3 quarters · filed 2026-02-24 | -$21.61M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-03-31 | $3.60M 10-Q · filed 2025-05-08 | -$10.33M derived: sum of 2 quarters · filed 2026-02-24 | -$19.48M derived: sum of 3 quarters · filed 2026-02-24 | -$20.71M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2023-12-31 | -$13.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$23.09M derived: sum of 2 quarters · filed 2026-02-24 | -$24.32M derived: sum of 3 quarters · filed 2026-02-24 | -$18.25M 10-K · filed 2026-02-24 | -$8.98M 10-K · filed 2024-02-20 | ||
| 2023-09-30 | -$9.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$10.38M derived: sum of 2 quarters · filed 2024-11-04 | -$4.32M 10-Q · filed 2024-11-04 | -$4.17M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | -$1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.83M 10-Q · filed 2024-08-06 | $4.98M derived: sum of 3 quarters · filed 2025-02-27 | $2.07M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | $6.06M 10-Q · filed 2024-05-07 | $6.21M derived: sum of 2 quarters · filed 2025-02-27 | $3.30M derived: sum of 3 quarters · filed 2025-02-27 | -$119.00K derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$2.76M derived: sum of 2 quarters · filed 2025-02-27 | -$6.18M derived: sum of 3 quarters · filed 2025-02-27 | $1.38M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$2.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$6.33M derived: sum of 2 quarters · filed 2023-11-02 | $1.23M 10-Q · filed 2023-11-02 | $822.00K derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2022-06-30 | -$3.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $4.14M 10-Q · filed 2023-08-03 | $3.73M derived: sum of 3 quarters · filed 2024-02-20 | $3.40M derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2022-03-31 | $7.56M 10-Q · filed 2023-05-04 | $7.15M derived: sum of 2 quarters · filed 2024-02-20 | $6.82M derived: sum of 3 quarters · filed 2024-02-20 | $6.55M derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2021-12-31 | -$404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$740.00K derived: sum of 2 quarters · filed 2024-02-20 | -$1.01M derived: sum of 3 quarters · filed 2024-02-20 | $3.38M 10-K · filed 2024-02-20 | |||
| 2021-09-30 | -$336.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$607.00K derived: sum of 2 quarters · filed 2022-11-08 | $3.79M 10-Q · filed 2022-11-08 | $3.46M 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | -$271.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $4.12M 10-Q · filed 2022-08-09 | $3.76M 10-Q · filed 2021-08-13 | ||||
| 2021-03-31 | $4.39M 10-Q · filed 2022-05-10 | ||||||
| 2020-09-30 | -$964.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $898.00K 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $1.86M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |